KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBIT: 2020-2025

Historic EBIT for Ginkgo Bioworks Holdings (DNA) over the last 5 years, with Sep 2025 value amounting to -$90.0 million.

  • Ginkgo Bioworks Holdings' EBIT fell 63.06% to -$90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.1 million, marking a year-over-year increase of 45.11%. This contributed to the annual value of -$559.8 million for FY2024, which is 35.24% up from last year.
  • Per Ginkgo Bioworks Holdings' latest filing, its EBIT stood at -$90.0 million for Q3 2025, which was down 37.34% from -$65.5 million recorded in Q2 2025.
  • Ginkgo Bioworks Holdings' 5-year EBIT high stood at -$26.7 million for Q3 2021, and its period low was -$1.7 billion during Q4 2021.
  • Moreover, its 3-year median value for EBIT was -$178.0 million (2024), whereas its average is -$151.7 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 2,914.48% in 2021, then spiked by 86.30% in 2022.
  • Ginkgo Bioworks Holdings' EBIT (Quarterly) stood at -$1.7 billion in 2021, then surged by 86.30% to -$230.9 million in 2022, then climbed by 22.85% to -$178.1 million in 2023, then skyrocketed by 41.83% to -$103.6 million in 2024, then slumped by 63.06% to -$90.0 million in 2025.
  • Its last three reported values are -$90.0 million in Q3 2025, -$65.5 million for Q2 2025, and -$89.0 million during Q1 2025.